- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
More ▼
Key statistics
On Saturday, XOMA Corp (0M26:LSE) closed at 0.00, -100.00% above its 52-week low of 13.96, set on Oct 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 24.00 |
Average volume | -- |
---|---|
Shares outstanding | 11.64m |
Free float | 11.58m |
P/E (TTM) | -- |
Market cap | 293.29m USD |
EPS (TTM) | -3.92 USD |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼